Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Bonderman

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
Circulation|January 2, 2009
Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot studyNika Skoro-Sajer, Niklas Hack, Roela Sadushi-Koliçi, et al.
Frontiers in Cardiovascular Medicine|November 7, 2022
Heart failure with preserved ejection fraction: Calculating the risk of future heart failure events and deathLore Schrutka, Benjamin Seirer, René Rettl, et al.
The European Respiratory Journal|February 25, 2012
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertensionGérald Simonneau, Adam Torbicki, Marius M Hoeper, et al.
Hypertension (Dallas, Tex. : 1979)|June 25, 2019
Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection FractionChristina Binder, Marko Poglitsch, Asan Agibetov, et al.
Heart Rhythm O2|March 30, 2026
OPTimizing Beta-Blocker Dosage in Women Using the Wearable Cardioverter-Defibrillator (OPT-BB Women): Study designValentina Kutyifa, Ashley E Burch, Andrea Russo, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|August 31, 2015
Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fractionGültekin Karakus, Andreas A Kammerlander, Stefan Aschauer, et al.
Circulation|June 19, 2013
Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic studyDiana Bonderman, Stefano Ghio, Stephan B Felix, et al.
JACC. Cardiovascular Imaging|December 17, 2018
Syncope: The Underestimated Threat in Severe Aortic StenosisGeorg Goliasch, Andreas A Kammerlander, Christian Nitsche, et al.
Radiology|June 1, 2017
Diameter of the Pulmonary Artery in Relation to the Ascending Aorta: Association with Cardiovascular OutcomeAndreas A Kammerlander, Stefan Aschauer, Caroline Zotter-Tufaro, et al.
Wiener Klinische Wochenschrift|September 4, 2016
Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trialJulia Mascherbauer, Ekkehard Grünig, Michael Halank, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Circulation|January 2, 2009
Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot studyNika Skoro-Sajer, Niklas Hack, Roela Sadushi-Koliçi, et al.
Frontiers in Cardiovascular Medicine|November 7, 2022
Heart failure with preserved ejection fraction: Calculating the risk of future heart failure events and deathLore Schrutka, Benjamin Seirer, René Rettl, et al.
The European Respiratory Journal|February 25, 2012
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertensionGérald Simonneau, Adam Torbicki, Marius M Hoeper, et al.
Hypertension (Dallas, Tex. : 1979)|June 25, 2019
Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection FractionChristina Binder, Marko Poglitsch, Asan Agibetov, et al.
Heart Rhythm O2|March 30, 2026
OPTimizing Beta-Blocker Dosage in Women Using the Wearable Cardioverter-Defibrillator (OPT-BB Women): Study designValentina Kutyifa, Ashley E Burch, Andrea Russo, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|August 31, 2015
Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fractionGültekin Karakus, Andreas A Kammerlander, Stefan Aschauer, et al.
Circulation|June 19, 2013
Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic studyDiana Bonderman, Stefano Ghio, Stephan B Felix, et al.
JACC. Cardiovascular Imaging|December 17, 2018
Syncope: The Underestimated Threat in Severe Aortic StenosisGeorg Goliasch, Andreas A Kammerlander, Christian Nitsche, et al.
Radiology|June 1, 2017
Diameter of the Pulmonary Artery in Relation to the Ascending Aorta: Association with Cardiovascular OutcomeAndreas A Kammerlander, Stefan Aschauer, Caroline Zotter-Tufaro, et al.
Wiener Klinische Wochenschrift|September 4, 2016
Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trialJulia Mascherbauer, Ekkehard Grünig, Michael Halank, et al.
Pageof 13